

Multiple Sclerosis (MS)

## A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

**Trial Status**

Active, not recruiting

**Trial Runs In**

37 Countries

**Trial Identifier**

NCT05269004 2021-005746-15  
MN43964

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

### ***Trial Summary:***

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respective Parent study (WA21092, WA21093 or WA25046) are eligible for enrollment in this extension study. Participants who will continue ocrelizumab treatment will receive IMP based on the dosage and administration received at the time of rollover from the Parent study.

**Hoffmann-La Roche**

Sponsor

**Phase 3**

Phase

NCT05269004 2021-005746-15 MN43964

Trial Identifiers

### ***Eligibility Criteria:***

**Gender**

All

**Age**

>=18 Years

**Healthy Volunteers**

No